In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors
Advanced Materials · 2023
DOI: 10.1002/adma.202300171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2023. Verfasst von Beibei Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, 450003, Zhe…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Science and Technology Department of Henan Province, the Postdoctoral Science Foundation of China, Start-up Grant from Zhengzhou University.
Abstract (Originalsprache)
Immunotherapies comprising programmed cell death protein 1/PD ligand 1 (PD‐1/PD‐L1) immune checkpoint inhibitors are effective cancer treatments. However, the low response rate and immunoresistance resulting from alternative immune checkpoint upregulation and inefficient immune stimulation by T cells are problematic. The present report describes a biomimetic nanoplatform that simultaneously blocks the alternative T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) checkpoint and activates the stimulator of interferon genes (STING) signaling pathway in situ for enhanced antitumor immunity. The nanoplatform is engineered by fusing a red blood cell membrane with glutathione‐responsive liposome‐encapsulated cascade‐activating chemoagents ( β ‐lapachone and tirapazamine), and anchoring them with a detachable TIGIT block peptide (named as RTLT). In the tumor environment, the peptide is spatiotemporally released to reverse T‐cell exhaustion and restore antitumor immunity. The cascade activation of chemotherapeutic agents causes DNA damage and inhibits the repair of double‐stranded DNA, which induces robust in situ STING activation for an efficient immune response. The RTLT inhibits anti‐PD‐1‐resistant tumor growth, and prevents tumor metastasis and recurrence in vivo by inducing antigen‐specific immune memory. This biomimetic nanoplatform thus provides a promising strategy for in situ cancer vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, 450003, Zhengzhou, China.
- School of Biological Engineering, Henan University of Technology, 450001, Zhengzhou, China.
- School of Life Sciences, Zhengzhou University, 450001, Zhengzhou, China.
ORCID-Profile: Beibei Zhang, Lianzhong Zhang
Förderung
- Science and Technology Department of Henan Province
- the Postdoctoral Science Foundation of China
- Start-up Grant from Zhengzhou University
- Key Research and Development Projects in Henan Province
- National Natural Science Foundation of China
- Medical Science and Technology Breakthrough Plan Project of Henan Province
Zitieren
APA
Zhang, B., Zhang, J., Li, Y., Li, N., Wang, Y., Jang, R., Xu, X., Li, R., Chen, Z., Duan, S., Wang, Y., & Zhang, L. (2023). In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors. Advanced Materials. https://doi.org/10.1002/adma.202300171
Vancouver
Zhang B, Zhang J, Li Y, Li N, Wang Y, Jang R, et al. In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors. Advanced Materials. 2023. doi:10.1002/adma.202300171
BibTeX
@article{Zhang2023,
author = {Zhang, Beibei and Zhang, Juan and Li, Yaqiong and Li, Na and Wang, Yuzhou and Jang, Ru and Xu, Xiaoxia and Li, Ruifang and Chen, Zhenzhen and Duan, Shaobo and Wang, Yongchao and Zhang, Lianzhong},
title = {In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors},
journal = {Advanced Materials},
year = {2023},
doi = {10.1002/adma.202300171}
}
EUVIMED